Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGF MDI versus BFF MDI and Symbicort pMDI in inadequately controlled asthma
2020-001520-34Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in asthma and severe asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary end point(s) of D5982C00007. Started Dec 2020; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on 2020-001520-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001520-34.